health plans and consumers. The Subcommittee will invite representatives of affected groups to provide information about how the regulation has affected the level of privacy and confidentiality for protected health information, best practices for implementation of the regulation, and information that might help to identify and resolve barriers to compliance. The format will include one or more invited panels and time for questions and discussion. The Subcommittee will ask the invited witnesses for examples of the effect the regulation has had on individuals and on entities subject to the regulation. The first day will also include a time period during which members of the public may deliver brief (3 minutes or less) oral public comment about the implementation of the regulation. To be included on the agenda, please contact Marietta Squire (301) 458-4524, by e-mail at mrawlinson@cdc.gov or postal address at 3311 Toledo Road, Room 2340, Hyattsville, MD 20782 by November 12, 2003.
The second day of the meeting will be conducted in two parts. The first part will be a hearing in which the Subcommittee will gather information about the effects of the regulation on organizations involved in health research activities. The Subcommittee will invite representatives of affected groups to provide information about how the regulation has affected the level of privacy and confidentiality for protected health information, best practices for implementation of the regulation, and information that might help to identify and resolve barriers to compliance. The second part will consist of Subcommittee discussion of the testimony it has heard and deliberations about possible recommendations to the Secretary.
Persons wishing to submit written testimony only (which should not exceed five double-spaced typewritten pages) should endeavor to submit it by that date. Unfilled slots for oral testimony will also be filled on the days of the meeting as time permits. Please consult Ms. Squire for further information about these arrangements.
Additional information about the hearing will be provided on the NCVHS Web site at http://www.ncvhs.hhs.gov shortly before the hearing date.
FOR FURTHER INFORMATION CONTACT:
Information about the content of the hearing and matters to be considered may be obtained Table 6 entitled ''EPR determined and X-ray crystal modeled inter-nitroxide distances of PGHS-2 MBD mutants''); II. JBC paper Table III entitled ''Changes in inter-nitroxide differences between PGHS-2 holoenzyme and the apoenzyme, and the arachidonate, flurbiprofen, and SC58125 complexes'' (and corresponding Dissertation Table  7) , entitled ''Relative changes in internitroxide distances for NSAID and arachidonate complexes compared to the unliganded enzyme''); III. JBC paper Figure 4 (binding curves) (and corresponding Dissertation Figure 20 entitled ''Binding curves for the association of heme, flurbiprofen and arachidonic acid with PGHS-2 double mutants'');
IV. Dissertation Table 8 entitled ''EPR determined inter-nitroxide distances for NSAID and arachidonate complexes of PGHS-2 MBD mutants;' V. Dissertation Table 9 entitled ''Relative changes in inter-nitroxide distances for NSAID and arachidonate complexes compared to the unliganded enzyme;' VI. Dissertation Table 10 entitled ''Kinetic properties and NSAID sensitivities of PGHS-2 active site mutants;'' VII. Dissertation Table 12 entitled ''Relative PGHS-2 protein incorporation of PGHS-2 into lipsomes of varying composition;'' IX. Dissertation Table 13 entitled ''EPR determined inter-nitroxide distances for detergent solubilized and lipsome reconstituted PGHS-2 mutants;'' and X. Dissertation Figure 27 entitled ''Lipid and activity profile of sucrose gradient fractions.''
The research misconduct was significant for several reasons. First, the JBC paper was novel in that it reported that binding of arachidonate and NSAIDs induced structural changes in PHS-2. For the naturally occurring fatty acid arachidonate, this had not previously been shown. These results could be interpreted as having important implications for understanding the catalytic mechanism of this enzyme. In addition, a considerable expenditure of other researchers' time and resources was prompted by using results generated from the falsified and fabricated data in the JBC paper.
Dr. Smith has entered into a Voluntary Exclusion Agreement (Agreement ) in which he has voluntarily agreed:
(1) to exclude himself from serving in any advisory capacity to PHS including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) 
